HURANasdaqPharmaceutical PreparationsFiscal year ends December 31
TuHURA Biosciences, Inc./NV
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.78+0.02 (+1.14%)
Close on Oct 19, 2026
- Market cap
- $113.86M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.62 (−25.83%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
TuHURA Biosciences, Inc./NV reported revenue of $0 for fiscal 2025. Free cash flow was -$29.90M.
Revenue
$0
FY2025
Free cash flow
-$29.90M
TTM Q2 2026
EPS, diluted
-$0.54
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $113.86M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.15
- Dividend yield
- –
- Free cash flow yield
- -26.26%
Fundamentals
- Revenue
- $0
- Net income
- -$30.62M
- EPS, diluted
- -$0.54
- Free cash flow
- -$29.90M
- Book value per share
- $0.29
- Diluted shares
- 64M
Thirteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
–
Net income
-$30.62M
EPS, diluted
-$0.54
Free cash flow
-$29.90M
Reported periodTrailing twelve months